Bio-Techne Corp (TECH): Price and Financial Metrics

Bio-Techne Corp (TECH)

Today's Latest Price: $303.74 USD

1.16 (-0.38%)

Updated Nov 23 4:00pm

Add TECH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

TECH Stock Summary

  • Price to trailing twelve month operating cash flow for TECH is currently 51.03, higher than 92.42% of US stocks with positive operating cash flow.
  • TECH's price/sales ratio is 15.5; that's higher than the P/S ratio of 89.87% of US stocks.
  • Over the past twelve months, TECH has reported earnings growth of 136.83%, putting it ahead of 90.68% of US stocks in our set.
  • Stocks that are quantitatively similar to TECH, based on their financial statements, market capitalization, and price volatility, are HZNP, RP, SPSC, AKAM, and FICO.
  • Visit TECH's SEC page to see the company's official filings. To visit the company's web site, go to

TECH Stock Price Chart Interactive Chart >

Price chart for TECH

TECH Price/Volume Stats

Current price $303.74 52-week high $316.87
Prev. close $304.90 52-week low $155.17
Day low $300.54 Volume 133,900
Day high $305.56 Avg. volume 211,032
50-day MA $268.29 Dividend yield 0.42%
200-day MA $244.26 Market Cap 11.73B

Bio-Techne Corp (TECH) Company Bio

Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.

TECH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$303.74$45.99 -85%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for BIO-TECHNE Corp. To summarize, we found that BIO-TECHNE Corp ranked in the 14th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of BIO-TECHNE Corp, consider:

  • The company's balance sheet shows it gets 97% of its capital from equity, and 3% of its capital from debt. Notably, its equity weight is greater than 78.63% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than merely 12.07% of the free cash flow producing stocks we're observing.
  • TECH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.61% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of BIO-TECHNE Corp? See ZBH, BSX, QGEN, SIGA, and IDXX.

TECH Latest News Stream

Event/Time News Detail
Loading, please wait...

TECH Latest Social Stream

Loading social stream, please wait...

View Full TECH Social Stream

Latest TECH News From Around the Web

Below are the latest news stories about BIO-TECHNE Corp that investors may wish to consider to help them evaluate TECH as an investment opportunity.

Bio-Techne Announces Opening Of New Canadian Facility

MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace for approximately 40 Bio-Techne employees and reflects the Company's commitment to supporting the…

PR Newswire | October 1, 2020

Bio-Techne Announces Grand Opening Of GMP Manufacturing Facility

MINNEAPOLIS, Sept. 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing Practices) manufacturing facility. Located in St. Paul, MN, the new facility is dedicated to…

PR Newswire | September 30, 2020

Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy

MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy…

PR Newswire | September 23, 2020

Bio-Techne launches new co-detection assays

Bio-Techne (TECH) announces the commercial launch of new RNA-Protein Co-Detection Assays that enable visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues.The company says the research-use-only tests allow researchers to simultaneously examine cell-type specific gene expression and identify cellular sources of secreted proteins....

Seeking Alpha | September 22, 2020

Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample

MINNEAPOLIS, Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAscope technology is an advanced in situ…

PR Newswire | September 22, 2020

Read More 'TECH' Stories Here

TECH Price Returns

1-mo 13.26%
3-mo 21.18%
6-mo 18.33%
1-year 41.67%
3-year 135.17%
5-year 247.20%
YTD 39.07%
2019 52.67%
2018 12.60%
2017 27.40%
2016 15.77%
2015 -1.29%

TECH Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TECH Dividend History

Continue Researching TECH

Want to see what other sources are saying about BIO-TECHNE Corp's financials and stock price? Try the links below:

BIO-TECHNE Corp (TECH) Stock Price | Nasdaq
BIO-TECHNE Corp (TECH) Stock Quote, History and News - Yahoo Finance
BIO-TECHNE Corp (TECH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0948 seconds.